Hepatic glucose production and storage as a potential strategy for type 2 diabetes treatment - The effect of catestatin - "just another new kid in town?"
- PMID: 35224867
- DOI: 10.1111/apha.13808
Hepatic glucose production and storage as a potential strategy for type 2 diabetes treatment - The effect of catestatin - "just another new kid in town?"
Comment on
-
Catestatin induces glycogenesis by stimulating the phosphoinositide 3-kinase-AKT pathway.Acta Physiol (Oxf). 2022 May;235(1):e13775. doi: 10.1111/apha.13775. Epub 2022 Feb 4. Acta Physiol (Oxf). 2022. PMID: 34985191 Free PMC article.
Similar articles
-
Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules.J Biol Chem. 2000 Jul 28;275(30):22905-15. doi: 10.1074/jbc.M001232200. J Biol Chem. 2000. PMID: 10781584
-
Catestatin Induces Glucose Uptake and GLUT4 Trafficking in Adult Rat Cardiomyocytes.Biomed Res Int. 2018 Oct 2;2018:2086109. doi: 10.1155/2018/2086109. eCollection 2018. Biomed Res Int. 2018. PMID: 30370303 Free PMC article.
-
Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome.Biomed Pharmacother. 2021 Feb;134:111113. doi: 10.1016/j.biopha.2020.111113. Epub 2020 Dec 16. Biomed Pharmacother. 2021. PMID: 33341043 Review.
-
Catestatin Inhibits Obesity-Induced Macrophage Infiltration and Inflammation in the Liver and Suppresses Hepatic Glucose Production, Leading to Improved Insulin Sensitivity.Diabetes. 2018 May;67(5):841-848. doi: 10.2337/db17-0788. Epub 2018 Feb 6. Diabetes. 2018. PMID: 29432123 Free PMC article.
-
Chromogranin A as biomarker in diabetes.Biomark Med. 2016 Nov;10(11):1181-1189. doi: 10.2217/bmm-2016-0091. Epub 2016 Sep 9. Biomark Med. 2016. PMID: 27611656 Review.
References
REFERENCES
-
- Bandyopadhyay G, Tang K, Webster NJG, van den Bogaart G, Mahata SK. Catestatin induces glycogenesis by stimulating the phosphoinositide 3-kinase-AKT pathway. Acta Physiol (Oxf). 2022;5:e13775. doi:10.1111/apha.13775
-
- Ying W, Mahata S, Bandyopadhyay GK, et al. Catestatin inhibits obesity-induced macrophage infiltration and inflammation in the liver and suppresses hepatic glucose production, leading to improved insulin sensitivity. Diabetes. 2018;67(5):841-848. doi:10.2337/db17-0788
-
- Bourebaba Y, Mularczyk M, Marycz K, Bourebaba L. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome. Biomed Pharmacother. 2021;134:111113. doi:10.1016/j.biopha.2020.111113
-
- Simunovic M, Supe-Domic D, Karin Z, et al. Serum catestatin concentrations are decreased in obese children and adolescents. Pediatr Diabetes. 2019;20(5):549-555. doi:10.1111/pedi.12825
-
- Nagasawa S, Nishikawa Y, Jun L, et al. Simple enzyme immunoassay for the measurement of immunoreactive chromogranin A in human plasma, urine and saliva. Biomed Res. 1998;19:407-410.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical